In the SURMOUNT-1 study, in fact, over 95% of participants with prediabetes were able to achieve normalization of blood glucose after 72 weeks of treatment with tirzepatide, the first GIP/GLP-1 receptor co-agonist representing this new class of drugs, compared to 62% of the control group [57]. Here, GLP1R is linked to prediabetes syndrome.